bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.05.20.726540

Large-Scale Assessment of Animal-to-Human Drug Translation Using Natural Language Processing

Abstract

BackgroundLarge-scale estimates of animal-to-human drug translation and the study characteristics associated with successful translation remain limited. The expanding preclinical literature also challenges manual evidence synthesis. We developed a natural language processing (NLP) pipeline to structure and link preclinical and clinical evidence at scale. MethodsIn this retrospective meta-research study, we analysed more than 500,000 neuroscience-related animal drug studies from PubMed and linked them to clinical trial and regulatory approval data. NLP methods extracted drug, disease, and experimental design characteristics from abstracts and full texts. Translation was defined as progression to completed phase III/IV trials or regulatory approval. Logistic regression assessed associations between preclinical study characteristics and successful translation. FindingsAmong 291,624 drug entities identified in animal studies, 6{middle dot}7% entered clinical development and 3{middle dot}1% reached phase III/IV trials or regulatory approval. At the drug-disease level, 4{middle dot}4% entered clinical development and 1{middle dot}9% achieved translation. Restricting analyses to successfully linked ontology entities increased estimates to 11{middle dot}3% and 4{middle dot}1%, respectively. Male-only animal studies predominated, whereas reporting of randomisation, blinding, and sample size calculations remained limited. Testing across multiple species and reporting blinding were associated with higher odds of successful translation. InterpretationOnly a minority of interventions tested in animals progress to advanced clinical development or regulatory approval. Greater species diversity and blinding were associated with improved translational success. NLP-based evidence synthesis may support scalable evaluation of translational research and identification of potentially modifiable research practices. FundingSwiss National Science Foundation, UZH Digital Entrepreneurship Fellowship, Universities Federation for Animal Welfare. Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched the literature for studies quantifying large-scale animal-to-human translation and factors associated with successful translation. Existing work was mainly limited to specific diseases, interventions, or manually curated datasets, and large-scale linkage of animal and clinical evidence remained limited. Added value of this studyWe developed a natural language processing pipeline linking more than 500,000 animal studies to clinical trial and regulatory approval data. The study provides large-scale estimates of translation and identifies experimental characteristics associated with successful translation. Implications of all the available evidenceThe findings suggest that only a minority of interventions tested in animals progress to advanced clinical development or regulatory approval. Greater species diversity and reporting of blinding were associated with improved translation. Automated evidence synthesis may support more systematic evaluation of translational research practices.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Doneva, S. E., Ellendorff, T. R., Schneider, G., Held, L., von Wyl, V., Simpson, I., Sick, B., Ineichen, B. V.. 2026-05-22. Large-Scale Assessment of Animal-to-Human Drug Translation Using Natural Language Processing. https://doi.org/10.64898/2026.05.20.726540

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Heterogeneous Graph Contrastive Learning for Drug-Gene-Disease Motif Prediction

Drug repurposing and target discovery offer critical strategies for advancing therapeutic development by uncovering the potential biological pathways and novel associations among drugs, genes, and diseases. However, experimental discovery remains expensive and time-consuming, which limits the scalability of large-scale studies. In addition, existing computational approaches often struggle to effectively integrate heterogeneous biomedical data, capture the complex higher-order topological signatures of biological interactomes, and generalize to unseen entities. Here, we present HANAMI (Heterogeneous grAph coNtrastive leArning for drug-gene-disease Motif predIction), a multi-view deep graph learning framework designed to model complex interactions among drugs, genes, and diseases. HANAMI integrates diverse heterogeneous biomedical knowledge, including chemical structures, genomic sequences, and clinical phenotypes, and leverages relation-aware topology encoding, structure-aware aggregation, and contrastive learning to enable accurate motif prediction with biological context from the network. Systematic evaluation on benchmark datasets shows that HANAMI achieves up to 6% improvements over existing state-of-the-art methods in predicting drug-gene-disease motifs. The framework further demonstrates strong inductive generalization, maintaining an [~]18% performance advantage in zero-shot settings involving previously unseen entities. Beyond predictive performance, HANAMI effectively prioritizes drug-disease relationships investigated in Phase II or III trials while identifying candidate genes that suggest plausible mechanistic links. Together, HANAMI provides a computational framework for interpreting complex biomedical interactions, offering a scalable foundation to accelerate drug repurposing and therapeutic innovation.

bioinformatics↗

PTMExplorer: A Multi-Dimensional Integrative Visualization Platform for Protein Post-Translational Modification Function and Structure

Deciphering the functions of post-translational modifications (PTMs) is a critical bridge connecting large-scale modification proteomics data to mechanistic studies. However, most existing tools for visualizing PTM omics data are limited to site catalogs or single-dimensional feature displays. They lack the capability to simultaneously map user-derived differential modification sites onto multi-dimensional contexts, including protein three-dimensional (3D) structure, evolutionary conservation, functional sites, and disease associations. This limitation makes it difficult for researchers to rapidly assess the biological importance of candidate sites from among a vast number of differentially modified sites. Here, we present PTMExplorer, an interactive platform for the multi-dimensional visualization of protein PTMs. PTMExplorer comprises three core modules: PTM Inspector, built upon ProtVista, provides a multi-track, sequence-feature integrated view incorporating intrinsically disordered region (IDR) prediction (via flDPnn), surface accessibility calculation (via FreeSASA), and UniProt functional annotations; PTM 3D Locator, leveraging the Nightingale/Mol* engine, anchors modification sites onto AlphaFold/Protein Data Bank (PDB) 3D structures through residue mapping via PDBe-SIFTS; and PTM Overview, utilizing the R circlize package, presents a panoramic polar circos plot illustrating modification distribution and inter-group differential regulation. Additionally, three major disease-associated modification databases (PTMD, qPTM, and PhosCancer) are integrated as PTM-Disease Nexus, enabling co-localization comparison between user-defined differential sites and reported disease-related sites. PTMExplorer currently supports eight model organisms, accepts user-uploaded differential analysis results, and provides multi-dimensional annotations and various visualization options (https://www.bioladder.cn/PTMExplorer/). Using a multi-omics dataset from hepatocellular carcinoma (18 patients, 9 modification types) as a case study, we demonstrate the practical utility of PTMExplorer in screening potential biomarkers, revealing multi-modification coordination mechanisms, and distinguishing between absolute and relative quantification patterns.

bioinformatics↗

Integrative analysis of the MDM2 promoter switch and cellular lineage plasticity in colorectal cancer: a contrast between the autonomous-proliferation type (CIN/CMS2) and the environment-adaptive type (MSI/gastric metaplasia)

Background: Biomarkers that stratify colorectal cancer (CRC) by therapeutic responsiveness and are measurable directly in biopsy specimens remain insufficiently established. We investigated whether usage of the dual MDM2 promoters (P1/P2) acts as a molecular switch separating two diametrically opposed CRC phenotypes: a chromosomal instability type and an environment adaptive type (microsatellite instability/serrated pathway with gastric metaplasia). Methods: Sixty three organoid samples from 22 patients with CRC were classified morphologically by deep learning (VGG16) and molecularly by an MDM2 Splicing Index derived from expression arrays. The P1 and P2 signatures (gene sets characterizing P1 and P2dominant samples) were externally validated in TCGA-COAD/READ (n = 624) and GSE39582 (n = 536), 1,160 cases in total, and therapeutic implications were tested in public cell line panels (GDSC2, DepMap) and in 65 lines of an independent patient derived CRC organoid biobank. Results: Deep learning morphological classification reached 98.5% test accuracy (64/65), and morphology corresponded to P1/P2 isoform usage: Type1 (compact glandular) morphology predominated in P1 dominant samples (median Type1 fraction 0.826 versus 0.444) and non Type1 (cystic mucinous) morphology in P2 dominant samples (AUC 0.79). Both signatures differed across the four consensus molecular subtypes , and the P2 signature was higher in mismatch repair deficient (microsatellite-unstable) tumors. Promoter usage quantified directly (P2_index) was higher in TP53 wild type tumors , consistent with P2 being p53-inducible. TP53 wild type cell lines were more sensitive to the MDM2 inhibitor Nutlin 3a and were more dependent on MDM2 in the DepMap CRISPR screen ; among 198 GDSC2 drugs, Nutlin 3a correlated most strongly with the P2 score. In the independent biobank, TP53 wild type lines (17) were more sensitive to nutlin-3 than mutant lines (48) (median log(IC50) 1.386 versus 4.283). Conclusions: MDM2 promoter choice (P1/P2) co-varies with the lineage identity of cancer cells and with the secretory, mucin rich character of the tumor tissue, consistent with a molecular-switch role alongside p53 suppression. The MDM2 P1/P2 ratio, measurable by RT qPCR or targeted NGS, is a candidate molecular-classification and therapeutic-stratification biomarker corresponding robustly to CMS, MSI, and TP53 mutation status.

bioinformatics↗